Viberzi® (eluxadoline) – New warning

- On April 13, 2018, the FDA approved an update to the Warnings and Precautions section of the Viberzi (eluxadoline) drug label regarding constipation.

- Viberzi is approved in adults for the treatment of irritable bowel syndrome with diarrhea.

- Constipation, sometimes requiring hospitalization, has been reported following Viberzi administration. In postmarketing experience, severe cases with development of intestinal obstruction, intestinal perforation, and fecal impaction, requiring intervention, have also been reported.

  — Patients should be instructed to stop Viberzi and immediately contact their healthcare provider if they experience severe constipation.
  — Viberzi use should be avoided with other drugs that may cause constipation.